EN DE

ENBIO Co (352940) Fair Value & Analysis

Basic Materials · KR · Market cap 21.9B KRW

EC ENBIO Co 352940 · KQ
Price1,992 KRW
Fair Value1,576 KRW
Upside-20.9%
Quality50/100
Watch ENBIO Co for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 2.3% net margin
Low debt · generates free cash flow
Trails peers (3/10)
Narrow moat 38/100
Evidence: High Range 1,182 KRW – 1,970 KRW Share as image

Fair value as of: Jul 22, 2026

From 21 valuation models · updated 19 days ago

Share price −1.1% over the past month.

A solid business, but screening 21% overvalued on our models.

What matters now

  • Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
  • Our model range runs from 1,182 KRW (bear) to 1,970 KRW (bull), base 1,576 KRW. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 50/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

12,900 KRW 1,984 KRW Fair Value 1,576 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range 1,984 KRW – 12,900 KRW · fair‑value band 1,182 KRW – 1,970 KRW · the 1,992 KRW price screens above the 1,576 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

ENBIO Co (352940) currently trades at 1,992 KRW, while our model-based Fair Value estimate is 1,576 KRW, implying the stock looks roughly 20.9% overvalued today. The Quality Score stands at 50/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, ENBIO Co generated revenue of 34.3B KRW at a net margin of 2.3%. Revenue grew 2.2% year over year. It earns a return on equity of 1.8%. Net debt stands at 10.4B KRW. Fundamentals as of Jul 22, 2026

Our scenario range runs from 1,182 KRW (bear case) to 1,970 KRW (bull case); at 1,992 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -13% fair-value upside, at -21%, 352940 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 1,706 KRW 2,386 KRW 3,556 KRW 80
Rev-Margin DCF 948.14 KRW 1,353 KRW 1,867 KRW 74
ROIC Compounder 545.45 KRW 666.05 KRW 771.57 KRW 72
All 21 models by family
DCF Models
FCF DCF 1,623 KRW 2,323 KRW 3,629 KRW 38
5Y Revenue Exit 948.14 KRW 1,311 KRW 1,837 KRW 39
5Y EBITDA Exit 1,447 KRW 2,172 KRW 3,137 KRW 41
5Y P/E Exit 1,137 KRW 1,638 KRW 2,241 KRW 38
10Y Revenue Exit 1,179 KRW 1,478 KRW 1,786 KRW 36
10Y EBITDA Exit 1,502 KRW 2,014 KRW 2,556 KRW 37
10Y P/E Exit 1,314 KRW 1,681 KRW 2,025 KRW 35
Earnings-Based
Graham-Dodd 630.28 KRW 793.91 KRW 901.10 KRW 54
EPV 545.45 KRW 666.05 KRW 771.57 KRW 59
Multiples
P/E Multiple 1,182 KRW 1,576 KRW 1,970 KRW 63
P/S Multiple 1,182 KRW 1,576 KRW 1,970 KRW 58
P/B Multiple 1,182 KRW 1,576 KRW 1,970 KRW 55
EV/EBIT 708.26 KRW 1,004 KRW 1,299 KRW 53
EV/EBITDA 1,591 KRW 2,181 KRW 2,770 KRW 54
EV/Revenue 590.07 KRW 919.30 KRW 1,249 KRW 43
Asset-Based
NCAV (Graham) 1,949 KRW 2,611 KRW 3,898 KRW 50
Growth DCF
Growth DCF 1,706 KRW 2,386 KRW 3,556 KRW 80
Rev-Margin DCF 948.14 KRW 1,353 KRW 1,867 KRW 74
Economic Profit
Residual Income 2,771 KRW 2,650 KRW 2,143 KRW 61
ROIC Compounder 545.45 KRW 666.05 KRW 771.57 KRW 72
Growth Earnings
Growth-Adj P/E 841.91 KRW 1,203 KRW 1,564 KRW 68

Widest divergence: Asset-Based (2,611 KRW) versus Earnings-Based (666.05 KRW). Highest evidence: Growth DCF (80).

Notify me when 352940 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 34.3B KRW
Revenue growth (YoY) +2.2%
Net margin 2.3%
Return on equity 1.8%
Free cash flow 2.0B KRW FY2025
Operating margin 22.1%
More key figures
EPS growth (YoY) -8.6%
Net debt 10.4B KRW FY2025

Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 50/100

Of which business quality 49 · Market factors (momentum, volatility) 42

Profitability 26
Margins and returns on capital today
Quality Growth 39
Are margins and returns improving?
Cashflow 57
Earnings quality: real cash, not paper profit
Fin. Strength 40
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 88
Calm price path (market factor)
Momentum 25
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

ENBIO Co., Ltd. manufactures and sells pesticides and fertilizers in South Korea. The company provides lime sulfur, an eco-friendly crop protection agent containing sulfur; and Indoema, a broad-spectrum insecticide. It also offers disinfectant, pesticides, herbicides, growth regulator, for lawn, and trace element complex.

Full company description

ENBIO Co., Ltd. manufactures and sells pesticides and fertilizers in South Korea. The company provides lime sulfur, an eco-friendly crop protection agent containing sulfur; and Indoema, a broad-spectrum insecticide. It also offers disinfectant, pesticides, herbicides, growth regulator, for lawn, and trace element complex. The company was founded in 1997 and is headquartered in Gunpo-si, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

ENBIO Co reported revenue of 34.0B KRW in FY2025 versus 33.5B KRW in FY2021, a compound +0.4%/yr. Reported net income was 1.0B KRW in FY2025, compounding −33.8%/yr from FY2021.

Growth Quality 39/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
34.0B KRW
Latest YoY
−4.8%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.3%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.4%
Avg. growth/yr (8Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.4%
Revenue +0.4%/yr
FY21 33.5B KRW
FY22 34.2B KRW
FY23 34.0B KRW
FY24 35.7B KRW
FY25 34.0B KRW
Net income −33.8%/yr
FY21 5.2B KRW
FY22 −3.4B KRW
FY23 −6.3B KRW
FY24 646M KRW
FY25 1.0B KRW

352940 screens 21% overvalued. Compare with Corteva, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "ENBIO Co Fair Value". https://www.fairvalue-calculator.com/stock/352940

Peer Group

Agricultural Inputs · 179 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 50 · Below median
Fair Value upside −21% · Below median
Return on equity (TTM) 2% · Below median
Return on assets 1% · Bottom 25%
Net margin (TTM) 2% · Below median
Operating margin (TTM) 22% · Top 25%
Revenue growth 2% · Below median
Debt / equity 0.11× · Higher than median

Valuation Multiples vs Agricultural Inputs median · lower = cheaper

P/FCF 0.0× · Cheaper than 75% of peers
EV/EBITDA 0.8× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 5 · sector 21
FUTURE 11 · sector 37
PAST 7 · sector 24
HEALTH 94 · sector 97
DIVIDEND 0 · sector 33

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Stock Price Fair Value vs Fair Value
Corteva, Inc CTVA $86.07 $27.81 -68%
Nutrien Ltd NTR C$94.23 C$81.69 -13%
Qinghai Salt Lake Industry Co 000792 ¥24.93 ¥21.26 -15%
CF Industries Holdings CF $119.19 $161.00 +35%
SABIC Agri-Nutrients Company 2020 122.90 SAR 127.31 SAR +4%
Yara International ASA YAR kr 451.30 kr 67.25 -85%
Yunnan Yuntianhua Co 600096 ¥30.17 ¥42.12 +40%
Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 ¥42.59 ¥38.01 -11%
Coromandel International Limited COROMANDEL ₹2,034 ₹1,129 -44%
UPL Limited UPL ₹594.75 ₹387.06 -35%

Compare ENBIO Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is ENBIO Co (352940) overvalued or undervalued?
As of Jul 22, 2026, our model estimates a fair value of 1,576 KRW versus a price of 1,992 KRW, about −21% (overvalued).
What is the fair value of 352940?
Our model-based fair value for ENBIO Co is 1,576 KRW (as of Jul 22, 2026), built from audited fundamentals. The current price is 1,992 KRW.
What is the quality score of 352940?
ENBIO Co has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of ENBIO Co (352940)?
ENBIO Co reported trailing-twelve-month revenue of about 34.3B KRW (latest available figure, as of Jul 22, 2026).
What is the net profit margin of 352940?
The net profit margin of ENBIO Co is about 2.3%, meaning it keeps roughly 2.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track ENBIO Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.